{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:29:46Z","timestamp":1777858186472,"version":"3.51.4"},"reference-count":25,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2005,1]]},"abstract":"<jats:p>Infectious diseases, especially hepatitis C, are prevalent among drug abusers. Interferon-alpha (IFN-\u03b1) is the pharmacological treatment of choice for this condition. Patients being treated with IFN-\u03b1 can be expected to experience such psychiatric side-effects as development of depression, mania, irritability, changes in personality, hallucinations or delirium. In addition, certain patients are considered to be at greater risk of developing neuropsychiatric side-effects. Individuals meeting the following criteria are particularly vulnerable: over 40 years of age; having central nervous system abnormalities; a previous neurological or psychiatric history; a past familial psychiatric history; use of narcotics or having alcohol or substance use disorders; being HIV-positive; coadministration of other cytokines; receiving high doses of IFN-\u03b1 (&gt; 6 million units). We report the case of a 29-year-old patient with chronic non-active hepatitis C, a previous psychiatric history of polydrug abuse (cannabis, heroin and illegal use of the psychotropic drug biperiden) and anxiety disorder. Two weeks after the initiation of IFN-\u03b1 treatment, he developed fatigue, sleeplessness and persecutory delusions. The patient responded partially to the discontinuation of the IFN-\u03b1 treatment. Due to the presence of three risk factors in this patient, he was considered to belong to the group of patients being \u2018at high risk\u2019 of developing neuropsychiatric side-effects. This is the first case report of major depressive disorder with psychotic features in such a \u2018high-risk patient\u2019. This case report may prompt other research by showing the importance of the close monitoring, and the prevention of the progression of IFN-\u03b1-related psychiatric disorders in \u2018a high-risk patient\u2019.<\/jats:p>","DOI":"10.1177\/0269881105048905","type":"journal-article","created":{"date-parts":[[2005,1,25]],"date-time":"2005-01-25T11:53:59Z","timestamp":1106654039000},"page":"102-105","source":"Crossref","is-referenced-by-count":15,"title":["Major depressive disorder with psychotic features induced by                 interferon-\u03b1 treatment for hepatitis C in a polydrug abuser"],"prefix":"10.1177","volume":"19","author":[{"given":"O. Ayhan","family":"Kalyoncu","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Maltepe University Faculty of Medicine,                         Istanbul, Turkey,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devran","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Maltepe University Faculty of Medicine,                         Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan","family":"Mirsal","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Maltepe University Faculty of Medicine,                         Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozkan","family":"Pektas","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Maltepe University Faculty of Medicine,                         Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansur","family":"Beyazyurek","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Maltepe University Faculty of Medicine,                         Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2005,1,1]]},"reference":[{"key":"atypb1","first-page":"29","volume":"37","author":"Asnis G M","year":"2003","journal-title":"Psychopharmacol Bull"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(01)00553-3"},{"key":"atypb3","first-page":"1","volume":"19","author":"Consensus Statements: NIH Consensus Development Program","year":"2002","journal-title":"National Institutes of Health, Bethesda"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.6.867"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-4179(98)00073-4"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.41.5.439"},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2257.1994.tb00424.x"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1819.2000.00754.x"},{"key":"atypb9","doi-asserted-by":"publisher","DOI":"10.3109\/13651500009178004"},{"key":"atypb10","first-page":"319","volume":"3","author":"Katafuchi T","year":"1995","journal-title":"Neurobiology"},{"key":"atypb11","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(99)71208-9"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.1345\/aph.10172"},{"key":"atypb13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)91319-5"},{"key":"atypb14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.5.672"},{"key":"atypb15","first-page":"10","volume":"4","author":"Mirsal H","year":"2003","journal-title":"J Depend"},{"key":"atypb16","doi-asserted-by":"publisher","DOI":"10.2739\/kurumemedj.43.73"},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103293441303"},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.1997.tb02579.x"},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.3.429"},{"key":"atypb20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04793-X"},{"key":"atypb21","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1040523"},{"key":"atypb22","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1987.00370090055011"},{"key":"atypb23","first-page":"1101","volume":"95","author":"Schafer M","year":"2000","journal-title":"Addiction"},{"key":"atypb24","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C266"},{"issue":"1","key":"atypb25","first-page":"39","volume":"25","author":"Valentine A D","year":"1998","journal-title":"Semin Oncol"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881105048905","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881105048905","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:09:12Z","timestamp":1777507752000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0269881105048905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["10.1177\/0269881105048905"],"URL":"https:\/\/doi.org\/10.1177\/0269881105048905","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}